ClinicalTrials.gg
Status unknownNCT02496182PicheonUpdated Jul 14, 2015

Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment

A Phase 2/3 interventional study of Placebo and Pirfenidone in Alveolitis Extrinsic Allergic and Pulmonary Fibrosis, sponsored by Grupo Medifarma, S. A. de C. V.. Status unknown at 1 site in Mexico. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-07-14.

Sponsored by Grupo Medifarma, S. A. de C. V. · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2015), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Study summary

The Chronic Hypersensitivity Pneumonitis (HP), is an inflammatory disease who has an evolution to develop progressive interstitial fibrosis, who cause the death of the patient. Actually HP has been treated with Prednisone and occasionally with Azathioprine, but unfortunately the treatment with these drugs have not an effective result to treat the interstitial fibrosis.

Pirfenidone has been studied over the world for the treatment of Fibrotic diseases, with positive results, and due to the Pirfenidone mechanism of action has anti-inflammatory and anti-fibrotic properties, the investigators propose to evaluate the addition of Pirfenidone to the actual treatment with Prednisone and Azathioprine in the treatment of patients with Pulmonary Fibrosis secondary to a Chronic Hypersensitivity Pneumonitis.

Read the detailed description

The Chronic Hypersensitivity Pneumonitis (HP), is a complex syndrome due to a exaggerated immune response caused by inhalation of foreign substances, such as molds, dusts, and organic particles, causing alveoli inflammation and in the chronic forms the disease has high rate of mortality, due to the big number of patients who develop progressive interstitial fibrosis and eventually they curse with respiratory insufficiency who cause the death of the patient.

Pirfenidone has been studied over the world for the treatment of Idiophatic Pulmonary Fibrosis (IPF), disease who constitute the most aggressive of the fibrotic diseases of the lung. Additionally Pirfenidone has been showed potential results in the treatment of fibrotic diseases in other organs, as Liver, Kidney, Hearth, etc. Pirfenidone has been described as a modulator of the fibrotic process due to his action over TGF-beta and MMP´s and also has into-inflammatory actions acting over TNF-alfa and IL-1 and IL-6.

Actually HP has been treated with Prednisone and occasionally with Azathioprine, but a high number of patients will develop irreversibly to a interstitial fibrosis with pulmonary parenchyma destruction. Unfortunately the investigators have not an effective treatment for this cases. Due to the positive results obtained with Pirfenidone in the treatment of IPF and other kind of organ fibrosis, the investigators propose to evaluate the addition of Pirfenidone to the treatment with Prednisone and Azathioprine in the treatment of patients with Pulmonary Fibrosis secondary to a Chronic Hypersensitivity Pneumonitis.

02

Conditions studied

  • Alveolitis Extrinsic Allergic
  • Pulmonary Fibrosis
03

In context

Alveolitis, Extrinsic Allergic

34 studies on the registry are indexed under Alveolitis, Extrinsic Allergic; 11 are open to participants now.

This study's planned enrollment of 60 is above the median of 51 across 16 interventional studies indexed under Alveolitis, Extrinsic Allergic.

Browse Alveolitis, Extrinsic Allergic studies →

Lead sponsor

This is the only study on the registry with Grupo Medifarma, S. A. de C. V. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic pneumonitis with recent diagnosis confirmed by HRT with or without
  • Acceptation with signed

Exclusion criteria

Exclusion Criteria:

  • No confirmed diagnosis
  • Patients with peptic ulcer
  • Pregnancy or breast feeding period
  • Clinical signs of active infection
  • History of severe Hepatic disease
  • History of severe Kidney disease, who requires some kind of dialysis
  • History of inestable cardiopathy
  • History of alcohol or drugs abuse
  • Bronchial hyperactivity or History of asthma or EPOC
  • Smoking habit 3 months before the starting or patient who decline suspend the smoking habit during the study
  • Patient with impossibility to make spirometry or who can not walk
  • Use of , cytotoxic agents, cytosine modulators or receptor antagonist, fluvoxamine or daily use of sildenafil.
  • Patients who not accept sign the
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Conventional treatment (Prednisone 0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Placebo tablet 2 times at day.

    Drug: Placebo

  • Experimental
    Pirfenidone 1800 mg

    Conventional treatment (0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Pirfenidone long release tablet 900 mg 2 times at day, starting with 600 mg at day

    Drug: Pirfenidone

  • Experimental
    Pirfenidone 1200 mg

    Conventional treatment (0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Pirfenidone long release tablet 600 mg 2 times at day starting with 600 mg at day

    Drug: Pirfenidone

Interventions

  • DrugPlacebo

    Placebo tablet only with the excipients of the Pirfenidone tablet

    Also known as: Excipient Tablet

  • Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1800 mg

    Also known as: Kitoscell LP

  • Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1200 mg

    Also known as: KitosCell LP

06

What researchers measure

Primary outcomes

  1. Forced Vital Capacity (FVC)

    The measurement of FVC will be at 26 and 52 weeks

    Time frame: 52 weeks

Secondary outcomes

  1. High Resolution Tomography

    Evaluation of the inflammation and fibrosis grade with the Kazerooni scale

    Time frame: 52 weeks

  2. 6 minutes walk distance test

    quantification of the walking distance at 6 minutes

    Time frame: 52 weeks

  3. San George Qty Score, SOBQ and EQ5D Quality Scores

    As a composite outcome to evaluate the quality of life

    Time frame: 52 weeks

  4. Pulmonary artery systolic pressure with echocardiogram

    measurement of pressure

    Time frame: 52 weeks

  5. Oxygen desaturation in exercise

    Measurement of Oxygen

    Time frame: 52 weeks

07

Study locations

1 of 1 sites recruiting
  • Instituto Nacional de Enfermedades Respiratorias
    Mexico city, Distrito Federal 14080, Mexico
    Recruiting
    • Heidegger Mateos, MD · Contact+5255 5487 1771
    • Pedro Pena, MD · Contactpedropena@grupomedifarma.com · +5215591971972
    • Moises Selman Lama, PhD · Principal investigator
    • Mayra Mejia, MD · Sub investigator
    • Heidegger Mateo, MD · Sub investigator
    • Ivette Buendia, MD · Sub investigator
08

References and documents

Publications

  • Lacasse Y, Selman M, Costabel U, Dalphin JC, Ando M, Morell F, Erkinjuntti-Pekkanen R, Muller N, Colby TV, Schuyler M, Cormier Y; HP Study Group. Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2003 Oct 15;168(8):952-8. doi: 10.1164/rccm.200301-137OC. Epub 2003 Jul 3. PubMed 12842854 ↗
  • Selman M. Hypersensitivity pneumonitis: a multifaceted deceiving disorder. Clin Chest Med. 2004 Sep;25(3):531-47, vi. doi: 10.1016/j.ccm.2004.04.001. PubMed 15331190 ↗
  • Gaxiola M, Buendia-Roldan I, Mejia M, Carrillo G, Estrada A, Navarro MC, Rojas-Serrano J, Selman M. Morphologic diversity of chronic pigeon breeder's disease: clinical features and survival. Respir Med. 2011 Apr;105(4):608-14. doi: 10.1016/j.rmed.2010.11.026. Epub 2010 Dec 16. PubMed 21167698 ↗
  • Macias-Barragan J, Sandoval-Rodriguez A, Navarro-Partida J, Armendariz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair. 2010 Sep 1;3:16. doi: 10.1186/1755-1536-3-16. PubMed 20809935 ↗
  • Selman M, Pardo A, Richeldi L, Cerri S. Emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs. 2011 Jun;16(2):341-62. doi: 10.1517/14728214.2011.565049. Epub 2011 Mar 17. PubMed 21410428 ↗
  • Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011 Jun;20(120):85-97. doi: 10.1183/09059180.00001111. PubMed 21632796 ↗
  • Mateos-Toledo H, Mejia-Avila M, Rodriguez-Barreto O, Mejia-Hurtado JG, Rojas-Serrano J, Estrada A, Castillo-Pedroza J, Castillo-Castillo K, Gaxiola M, Buendia-Roldan I, Selman M. An Open-label Study With Pirfenidone on Chronic Hypersensitivity Pneumonitis. Arch Bronconeumol (Engl Ed). 2020 Mar;56(3):163-169. doi: 10.1016/j.arbres.2019.08.019. Epub 2019 Nov 26. English, Spanish. PubMed 31784348 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Jan 2016 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2015
First posted
Jul 14, 2015
Start
Jul 2015
Primary completionEst.
Jan 2016
CompletionEst.
Jan 2017
Last update
Jul 14, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02496182
Lead sponsor
Grupo Medifarma, S. A. de C. V.
Responsible party
Sponsor
First posted
Jul 14, 2015
Start date
Jul 2015
Primary completion
Jan 2016 (estimated)
Completion
Jan 2017 (estimated)
Last update
Jul 14, 2015

Study contacts

Pedro Pena, MD
Contact
pedropena@grupomedifarma.com
+52191971972
Jarod Escobar, MD
Contact
jarodescobar@cellpharma.com
+525515764477

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion